225 related articles for article (PubMed ID: 32317209)
1. Design, synthesis and antiproliferative activity evaluation of a series of pyrrolo[2,1-f][1,2,4]triazine derivatives.
Xiang HY; Chen YH; Wang Y; Zhang X; Ding J; Meng LH; Yang CH
Bioorg Med Chem Lett; 2020 Jun; 30(12):127194. PubMed ID: 32317209
[TBL] [Abstract][Full Text] [Related]
2. Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2.
Shi W; Qiang H; Huang D; Bi X; Huang W; Qian H
Eur J Med Chem; 2018 Oct; 158():814-831. PubMed ID: 30248654
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Characterization of New Series of 1,3-5-Triazine Hydrazone Derivatives with Promising Antiproliferative Activity.
H Al Rasheed HHA; M Malebari AM; A Dahlous KA; El-Faham A
Molecules; 2020 Jun; 25(11):. PubMed ID: 32545272
[TBL] [Abstract][Full Text] [Related]
4. Uses of cyclohexane-1,3-dione for the synthesis of 1,2,4-triazine derivatives as anti-proliferative agents and tyrosine kinases inhibitors.
Megally Abdo NY; Milad Mohareb R; Halim PA
Bioorg Chem; 2020 Apr; 97():103667. PubMed ID: 32087416
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity.
El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
Bioorg Chem; 2018 Feb; 76():154-165. PubMed ID: 29175587
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR.
Hu J; Zhang Y; Tang N; Lu Y; Guo P; Huang Z
Bioorg Med Chem; 2021 Feb; 32():115997. PubMed ID: 33440319
[TBL] [Abstract][Full Text] [Related]
7. Transforming Type II to Type I c-Met kinase inhibitors via combined scaffold hopping and structure-guided synthesis of new series of 1,3,4-thiadiazolo[2,3-c]-1,2,4-triazin-4-one derivatives.
El-Wakil MH; Teleb M
Bioorg Chem; 2021 Nov; 116():105304. PubMed ID: 34534756
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines.
Mojzych M; Šubertová V; Bielawska A; Bielawski K; Bazgier V; Berka K; Gucký T; Fornal E; Kryštof V
Eur J Med Chem; 2014 May; 78():217-24. PubMed ID: 24681986
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of novel 1,2,4-triazine scaffold as FAK inhibitors with antitumor activity.
Dao P; Lietha D; Etheve-Quelquejeu M; Garbay C; Chen H
Bioorg Med Chem Lett; 2017 Apr; 27(8):1727-1730. PubMed ID: 28284808
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities.
Nie Z; Perretta C; Erickson P; Margosiak S; Lu J; Averill A; Almassy R; Chu S
Bioorg Med Chem Lett; 2008 Jan; 18(2):619-23. PubMed ID: 18055206
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of novel series of 2H-benzo[b][1,4]oxazin-3(4H)-one and 2H-benzo[b][1,4]oxazine scaffold derivatives as PI3Kα inhibitors.
Dong FD; Liu DD; Deng CL; Qin XC; Chen K; Wang J; Song HR; Ding HW
Bioorg Med Chem; 2018 Aug; 26(14):3982-3991. PubMed ID: 29937355
[TBL] [Abstract][Full Text] [Related]
12. Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
Teng Y; Lu X; Xiao M; Li Z; Zou Y; Ren S; Cheng Y; Luo G; Xiang H
Eur J Med Chem; 2020 Aug; 199():112339. PubMed ID: 32402933
[TBL] [Abstract][Full Text] [Related]
13. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors.
El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
Bioorg Chem; 2017 Aug; 73():154-169. PubMed ID: 28715754
[TBL] [Abstract][Full Text] [Related]
14. Heterocyclization of 2-(2-phenylhydrazono)cyclohexane-1,3-dione to Synthesis Thiophene, Pyrazole and 1,2,4-triazine Derivatives with Anti-Tumor and Tyrosine Kinase Inhibitions.
Mohareb RM; Alwan ES
Anticancer Agents Med Chem; 2020; 20(10):1209-1220. PubMed ID: 32156245
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of alkyl substituted pyridino[2,3-D]pyrimidine compounds as PI3Kα/mTOR dual inhibitors with improved pharmacokinetic properties and potent in vivo antitumor activity.
Liu Y; Xia Q; Fang L
Bioorg Med Chem; 2018 Aug; 26(14):3992-4000. PubMed ID: 29945756
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.
Ding HW; Deng CL; Li DD; Liu DD; Chai SM; Wang W; Zhang Y; Chen K; Li X; Wang J; Song SJ; Song HR
Eur J Med Chem; 2018 Feb; 146():460-470. PubMed ID: 29407971
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, Structure and Antiproliferative Activity of New pyrazolo[4,3- e]triazolo[4,5-b][1,2,4]triazine Derivatives.
Mojzych M; Tarasiuk P; Karczmarzyk Z; Juszczak M; Rzeski W; Fruzinski A; Wozny A
Med Chem; 2018; 14(1):53-59. PubMed ID: 29065838
[TBL] [Abstract][Full Text] [Related]
18. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.
Shi X; Quan Y; Wang Y; Wang Y; Li Y
Bioorg Med Chem Lett; 2021 Feb; 33():127725. PubMed ID: 33316409
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, in-vitro antiproliferative activity and kinase profile of new picolinamide based 2-amido and ureido quinoline derivatives.
El-Damasy AK; Seo SH; Cho NC; Kang SB; Pae AN; Kim KS; Keum G
Eur J Med Chem; 2015 Aug; 101():754-68. PubMed ID: 26218653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]